Physician profile
Jerome Grove
NPI 1932153236
$21,236.43
in general payments reported to CMS, 2019-2025
49 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,204 · 2021: $1,036 · 2022: $933 · 2023: $1,080 · 2024: $1,883 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| West Therapeutics Development, LLC | $10,086.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,066.90 | 2019-2025 | Relistor |
| Abbvie INC. | $1,127.64 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $795.17 | 2019-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $669.17 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Nevro Corp. | $637.31 | 2019-2024 | Senza |
| Abbott Laboratories | $614.92 | 2020-2024 | Proclaim, Ensite, Eterna |
| Pfizer INC. | $473.97 | 2019-2025 | |
| Nalu Medical, INC. | $465.14 | 2021-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $431.69 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Saluda Medical Americas, INC. | $377.19 | 2024-2025 | Evoke |
| Allergan, INC. | $255.70 | 2019-2022 | |
| Daiichi Sankyo INC. | $232.98 | 2019 | |
| Mdd US Operations, LLC | $229.54 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $226.84 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Grove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.